Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
When glioblastoma comes back, families are often faced with a difficult question: what else is available?
Glioblastoma, or GBM, is an aggressive brain cancer, and recurrent disease can be particularly difficult to treat. Surgery, radiation, chemotherapy and other approaches may remain options depending on the individual case, but researchers are also investigating newer forms of immunotherapy.
One of those approaches is CAR-T therapy for glioblastoma. The science is promising enough to justify serious research, but it is still experimental. For a patient considering treatment abroad, understanding that distinction is important.
Key Takeaways |
|
What is CAR-T Therapy for Glioblastoma?
CAR-T stands for chimeric antigen receptor T-cell therapy.
The treatment begins with T cells, a type of immune cell. These cells are collected from the patient or, in some experimental approaches, from a donor. They are genetically modified so that they can recognize a particular molecule on tumor cells. The modified cells are then expanded and administered back to the patient.
CAR-T has produced major results in some blood cancers because those cancers often carry relatively consistent surface markers that can be targeted.
Glioblastoma is different.
It is a solid tumor, and the tumor cells can be biologically diverse. One part of a tumor may express a target while another part expresses little or none of it. The tumor can also create an immunosuppressive environment that makes it difficult for T cells to remain active.
A 2025 review of the first decade of clinical trials identified these issues—including tumor heterogeneity, antigen escape, limited CAR-T persistence and the difficulty of reaching the tumor—as some of the central challenges in GBM CAR-T research.
Which CAR-T Targets Are Being Studied for Glioblastoma?
Researchers are testing several different tumor targets rather than relying on one universal CAR-T product.
IL13Rα2
IL13Rα2 has been one of the most extensively investigated targets.
Research has found IL13Rα2 expression in many glioblastoma tumors, making it an attractive target for engineered T cells. Clinical studies have tested IL13Rα2 CAR-T using different routes of administration, including delivery directly into or around the tumor.
In a phase 1 study of 65 patients with high-grade glioma, locoregional IL13Rα2 CAR-T treatment produced stable disease or better in about half of evaluable patients. The study was primarily designed to investigate safety and feasibility rather than prove efficacy in a randomized comparison.
EGFR and EGFRvIII
Another major research target is EGFR, including the tumor-associated EGFRvIII alteration.
Earlier studies investigated EGFRvIII-targeted CAR-T in recurrent glioblastoma. More recent approaches have attempted to address a major weakness of single-target therapy: tumors can lose or reduce the target after treatment.
This is one reason researchers are now testing CAR-T cells capable of recognizing more than one tumor-associated target.
B7-H3
B7-H3 is another target being actively studied.
A phase 1 trial published in 2026 evaluated intracranial administration of autologous B7-H3 CAR-T cells in patients with recurrent glioblastoma whose tumors expressed B7-H3. The study enrolled 15 patients and delivered 72 intracranial infusions in total. The investigators reported no dose-limiting toxicities or maximum tolerated dose during the study.
The results are important as clinical evidence that intracranial B7-H3 CAR-T can be investigated in recurrent GBM, but they should not be interpreted as proof that the treatment is effective for all patients.
Other Targets
Clinical and experimental programs have also investigated HER2, GD2, EphA2, CD70, chlorotoxin-related targets and combinations of several targets.
This variety reflects one of the central problems in glioblastoma: researchers are still trying to determine which target—or combination of targets—can provide sufficiently broad and durable tumor recognition.
Does CAR-T Therapy Work for Glioblastoma?
The honest answer is: some patients in early clinical studies have responded, but CAR-T has not yet demonstrated consistent effectiveness across glioblastoma patients.
A 2025 review covering clinical trials conducted between 2015 and 2024 found that CAR-T could be administered safely through both systemic and locoregional routes, but clinical and radiographic responses varied. The review also highlighted inconsistent CAR-T persistence within patients.
More recent research has produced additional signals of activity.
For example, a phase 1 trial of bivalent CAR-T cells targeting EGFR and IL13Rα2 delivered the cells directly into the ventricular system. Eighteen patients with EGFR-amplified recurrent GBM received treatment. The maximum tolerated dose was identified, although grade 3 neurotoxicity occurred in 10 patients.
A 2026 review of the field reported that the 65-patient IL13Rα2 study achieved disease control in approximately half of evaluable patients, while newer multi-target approaches have produced early radiological responses that have often been transient.
These findings are encouraging from a research perspective. They also show why families should be careful with claims that CAR-T is a cure for glioblastoma. Current evidence does not support making that claim.
Why is CAR-T for Glioblastoma So Difficult?
The brain presents several challenges that researchers are trying to overcome.
Getting CAR-T Cells to The Tumor
Intravenous CAR-T cells have to reach a tumor inside the central nervous system. Researchers therefore increasingly investigate locoregional delivery, including intracavitary and intraventricular administration.
The objective is to place more therapeutic cells closer to the tumor rather than relying entirely on cells circulating through the bloodstream.
Tumor Heterogeneity
Not every glioblastoma cell necessarily carries the same target.
If CAR-T cells attack cells expressing one antigen but other tumor cells lack that antigen, those remaining cells may survive.
This phenomenon is commonly described as antigen escape and is one reason researchers are developing multi-target or bispecific CAR-T approaches.
The Tumor Microenvironment
Glioblastoma can create an environment that suppresses immune-cell activity.
Even if CAR-T cells reach the tumor, they may not remain active long enough or in sufficient numbers to produce durable tumor control. Researchers are therefore studying new CAR designs, combination therapies and different delivery strategies.
Brain-Specific Treatment Risks
Because treatment is being delivered near or inside the brain, neurological adverse events require particularly careful monitoring.
In the 2026 EGFR/IL13Rα2 intraventricular phase 1 study, grade 3 neurotoxicity occurred in 10 of 18 patients, although no grade 4–5 neurotoxicity was reported.
This illustrates why an experimental CAR-T program for glioblastoma needs appropriate neurosurgical, neuro-oncology and cellular-therapy expertise.
Is CAR-T Approved for Glioblastoma?
CAR-T is not an established standard treatment for glioblastoma.
This distinction is essential.
CAR-T products have been approved for particular blood-cancer indications in several countries. That does not mean the same technology is approved for routine treatment of glioblastoma.
For GBM, most CAR-T approaches remain in clinical research, particularly phase 1 and early phase 2 development. The purpose of these studies is to establish safety, dosing, feasibility and early evidence of activity before larger controlled studies can determine clinical benefit.
For a patient considering an overseas program, the right question is therefore not simply:
“Does this hospital offer CAR-T?”
It is:
“Is there a legitimate CAR-T program targeting my tumor, and does my medical profile meet its eligibility requirements?”
That usually requires reviewing the pathology, molecular testing, previous treatment history and current imaging.
Is CAR-T Therapy for Glioblastoma Available in China?
China has become an active research environment for experimental CAR-T approaches targeting glioblastoma.
Researchers in Beijing, Shenzhen and other Chinese centers have investigated different CAR-T platforms and tumor targets.
For example, investigators at Beijing Tiantan Hospital and the Beijing Neurosurgical Institute have reported early clinical research involving CD44/CD133-targeted locoregional CAR-T cells for recurrent glioblastoma. The first-in-human study was designed primarily to assess safety and treatment feasibility.
Chinese researchers have also published work involving EphA2-targeted CAR-T for recurrent GBM and IL13Rα2-targeted CAR-T development.
More recently, a Chinese phase 1 study of B7-H3-targeting CAR-T investigated intracranial administration for recurrent GBM. The study was published in Nature Medicine in August 2026.
There is also an ongoing Chinese phase 1 program involving Tris-CAR-T for recurrent glioblastoma, using locoregional administration.
However, research activity should not be confused with routine commercial availability. A specific program may have strict eligibility requirements, may only accept patients within a clinical study or regulated research pathway, and may not accept international patients.
What Should Patients Check Before Considering CAR-T in China?
If your family is exploring CAR-T therapy for glioblastoma in China, several questions should be answered before travelling.
1. Has the Tumor Been Tested for The Relevant Target?
Different CAR-T programs target different markers.
Depending on the study, this might involve testing for markers such as B7-H3, EGFR/EGFRvIII, IL13Rα2 or other targets.
A patient should not assume that one CAR-T treatment can be substituted for another.
2. Is the Disease Newly Diagnosed or Recurrent?
Many CAR-T studies have focused on recurrent or treatment-resistant glioblastoma, although some programs are also investigating newly diagnosed disease.
The distinction can significantly affect eligibility.
3. What Route of Administration is Being Used?
Ask whether the program uses intravenous, intracavitary, intratumoral or intraventricular administration.
These are not interchangeable approaches. Locoregional treatment can require neurosurgical procedures or placement of a delivery device.
4. What Evidence Supports the Specific CAR-T Product?
Families should ask for the actual clinical-trial identifier, phase of development, published data and eligibility criteria.
This is more useful than relying on broad statements such as "advanced CAR-T" or "next-generation CAR-T."
5. What Happens if The Patient is Not Eligible?
A reputable medical center should be able to explain whether another treatment, clinical trial or standard-of-care option may be more appropriate.
How ChinaCureLink Can Help International Patients Explore CAR-T for Glioblastoma
For an international family, finding a promising clinical program is only the beginning.
ChinaCureLink helps patients organize their medical information and communicate with Chinese hospitals and treatment programs to determine whether a particular pathway may be relevant.
Medical-Record Preparation
A glioblastoma case can involve pathology reports, MRI scans, molecular testing, surgical reports, radiation records and multiple lines of treatment.
ChinaCureLink can help organize the available medical documentation for submission to the appropriate medical team.
Exploring Potential CAR-T Programs
Because CAR-T programs can differ by target, delivery method and eligibility criteria, the appropriate program depends on the patient's individual case.
ChinaCureLink can help identify potential Chinese treatment pathways and coordinate communication with the relevant medical institution.
Coordinating Treatment Abroad
If a Chinese hospital agrees to evaluate the patient, international treatment involves much more than the medical appointment itself.
Translation, medical records, appointment scheduling, travel coordination and communication with the treating institution all need to be managed.
ChinaCureLink provides concierge coordination for international patients so families can focus on the medical decisions rather than navigating every administrative step alone.
CAR-T therapy for glioblastoma remains an evolving field. ChinaCureLink does not guarantee eligibility, treatment response or access to a particular program. The treating medical team must determine whether an individual patient is medically appropriate for any experimental or clinical-trial pathway.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Frequently Asked Questions
Is CAR-T Therapy Available for Glioblastoma?
CAR-T therapy is being investigated in clinical trials for glioblastoma, particularly recurrent disease. Research has explored targets including IL13Rα2, EGFR/EGFRvIII and B7-H3, using intravenous and intracranial delivery. It is not currently an established standard treatment for glioblastoma.
Can CAR-T Cure Glioblastoma?
Current clinical evidence does not establish CAR-T as a cure for glioblastoma. Some early studies have reported tumor responses or disease control in individual patients, but responses have varied and larger controlled studies are needed to determine how effective and durable the treatment can be.
What Type of CAR-T Is Used for Glioblastoma?
There is no single CAR-T product used universally for GBM. Research has investigated CAR-T cells targeting IL13Rα2, EGFR/EGFRvIII, B7-H3, HER2, GD2, EphA2 and other targets. Some newer approaches target more than one antigen to address tumor heterogeneity.
Can Glioblastoma Patients Receive CAR-T Treatment in China?
China has active clinical research involving CAR-T approaches for glioblastoma, including studies targeting B7-H3 and CD44/CD133. Whether an international patient can participate depends on the specific program, eligibility criteria, regulatory pathway and whether the center accepts international patients.
How Is CAR-T Delivered for Glioblastoma?
Researchers have used several routes, including intravenous, intratumoral, intracavitary and intraventricular administration. Locoregional approaches are being studied because delivering CAR-T cells closer to the tumor may help overcome some of the challenges associated with reaching tumors inside the brain.
What Records Are Needed to Explore CAR-T for Glioblastoma?
Typically, a medical team will need pathology and biopsy information, MRI imaging, molecular or biomarker testing where available, surgical history, radiation and chemotherapy records, current medications and recent clinical assessments. The exact requirements depend on the individual CAR-T program.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials — Molecular Therapy, 2025. PubMed — CAR-T therapy for glioblastoma review Full-text article — PMC
Chimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review — Neuro-Oncology Advances, 2025. Oxford Academic — Full article PubMed — Systematic review
CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives — iScience, 2026. PubMed — Full reference and abstract
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial — Nature Medicine, 2026.
Locoregional bi-specific CAR-T cells targeting CD44 and CD133 in recurrent glioblastoma — Beijing Neurosurgical Institute / Beijing Tiantan Hospital, 2024. PMC — Clinical trial report Oxford Academic — Neuro-Oncology article
Treatment Clinical Trials for Glioblastoma — U.S. National Cancer Institute. NCI — Glioblastoma clinical trials
Comments